AT493998T - Pharmaceutical composition with an exendin-4-peptide - Google Patents

Pharmaceutical composition with an exendin-4-peptide

Info

Publication number
AT493998T
AT493998T AT08016667T AT08016667T AT493998T AT 493998 T AT493998 T AT 493998T AT 08016667 T AT08016667 T AT 08016667T AT 08016667 T AT08016667 T AT 08016667T AT 493998 T AT493998 T AT 493998T
Authority
AT
Austria
Prior art keywords
exendin
peptide
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
AT08016667T
Other languages
German (de)
Inventor
Andrew A Young
Bronislava Gedulin
Nigel Robert Arnold Beeley
Kathryn S Prickett
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US69495496A priority Critical
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24790961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT493998(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of AT493998T publication Critical patent/AT493998T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/605Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
AT08016667T 1996-08-08 1997-08-08 Pharmaceutical composition with an exendin-4-peptide AT493998T (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US69495496A true 1996-08-08 1996-08-08

Publications (1)

Publication Number Publication Date
AT493998T true AT493998T (en) 2011-01-15

Family

ID=24790961

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97938261T AT417622T (en) 1996-08-08 1997-08-08 Regulation of gastrointestinal mobility
AT08016667T AT493998T (en) 1996-08-08 1997-08-08 Pharmaceutical composition with an exendin-4-peptide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97938261T AT417622T (en) 1996-08-08 1997-08-08 Regulation of gastrointestinal mobility

Country Status (11)

Country Link
US (6) US6858576B1 (en)
EP (2) EP0966297B2 (en)
JP (2) JP2001501593A (en)
AT (2) AT417622T (en)
AU (1) AU4063697A (en)
CA (1) CA2262647C (en)
DE (2) DE69739172D1 (en)
DK (2) DK2016950T3 (en)
ES (2) ES2359031T3 (en)
PT (1) PT966297E (en)
WO (1) WO1998005351A1 (en)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723694B2 (en) * 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DK2016950T3 (en) * 1996-08-08 2011-04-04 Amylin Pharmaceuticals Inc Pharmaceutical composition comprising an exendin-4 peptide
US6191102B1 (en) 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
AT304864T (en) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Use of exedines and their antagonists to reduce food consumption
EP1938831A1 (en) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
BR9811866A (en) * 1997-08-08 2000-08-15 Amylin Pharmaceuticals Inc Compounds agonists of exendin
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DE69839021T3 (en) * 1997-11-14 2013-08-08 Amylin Pharmaceuticals, Llc Novel exendin agonists
EP1938830A1 (en) * 1997-11-14 2008-07-02 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
AU2003200129B2 (en) * 1997-11-14 2006-06-22 Amylin Pharmaceuticals, Llc Novel Exendin Agonist Compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
EP1941900A1 (en) * 1997-11-14 2008-07-09 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
BR9815670A (en) * 1997-11-14 2000-10-17 Amylin Pharmaceuticals Inc Compounds agonists of exendin
AU2006225176B2 (en) * 1997-11-14 2009-01-08 Amylin Pharmaceuticals, Llc Novel exendin agonist compounds
AU759058C (en) * 1998-02-13 2005-09-15 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
JP2003522099A (en) * 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ Of glp-1 with delayed action profile glp-1 derivatives and exendin
DK1105460T3 (en) * 1998-08-10 2010-02-08 Us Gov Health & Human Serv Differentiation of non-insulin producing cells into insulin producing cells with GLP-1 or Exendin-4 and uses thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
AU775063C (en) * 1999-04-30 2005-05-12 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
CN1191273C (en) 1999-05-17 2005-03-02 康久化学公司 Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EP1270011A4 (en) * 2000-02-18 2003-06-11 Sumitomo Pharma Drugs for ameliorating impaired glucose tolerance
JP2004514462A (en) * 2000-03-03 2004-05-20 シー・アール・バード・インク Multiple suction ports with endoscopic tissue adhesion device
ES2435094T3 (en) * 2000-05-19 2013-12-18 C.R. Bard, Inc. Device and method of tissue capture and suturing
CA2434237C (en) 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
AT396202T (en) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Long acting glucagon-similar peptide-2 for the treatment of gastrointestinal diseases and disorders
KR101165431B1 (en) 2002-02-20 2012-07-12 에미스페어 테크놀로지스, 인코포레이티드 Method for administering glp-1 molecules
CA2490564A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
JP2006517908A (en) 2002-10-02 2006-08-03 ジーランド・ファーマ・ア/エス Stabilized exendin-4 compound
ES2320754T3 (en) * 2002-10-22 2009-05-28 Waratah Pharmaceuticals, Inc. Treatment of diabetes.
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
PT1687019T (en) 2003-11-20 2018-02-26 Novo Nordisk As Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
CA2554458A1 (en) * 2004-01-30 2005-08-11 Waratah Pharmaceuticals, Inc. The combined use of glp-1 agonists and gastrin for regulating blood glucose levels
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2330124B1 (en) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
AU2005235634B2 (en) 2004-04-23 2011-10-20 Conjuchem Biotechnologies Inc. Method for the purification of albumin conjugates
KR100637433B1 (en) 2004-05-24 2006-10-20 삼성에스디아이 주식회사 Light emitting display
US8172857B2 (en) * 2004-08-27 2012-05-08 Davol, Inc. Endoscopic tissue apposition device and method of use
EP2286838A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
SG157423A1 (en) 2004-12-02 2009-12-29 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
WO2006074051A2 (en) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
EP1845105A4 (en) 2005-01-14 2009-02-18 Wuxi Grandchamp Pharmaceutical Modified exendins and uses thereof
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
EP1853627A2 (en) 2005-02-11 2007-11-14 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
CN100429227C (en) * 2005-06-29 2008-10-29 常州制药厂有限公司 Exendin 4 polypeptide segment
WO2007024700A2 (en) 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
EP1933862B1 (en) * 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US20090181887A1 (en) * 2005-09-08 2009-07-16 Gastrotech Pharma A/S Use of a glp-1 molecule for treatment of biliary dyskinesia and/or biliary pain/discomfort
RS51319B (en) 2005-09-22 2010-12-31 Biocompatibles Uk Limited Glp-1(glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
EP1854455B1 (en) * 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
KR101106510B1 (en) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 Two-piece, internal-channel osmotic delivery system flow modulator
KR101193722B1 (en) 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 Exendin fusion proteins
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
PE20080840A1 (en) * 2006-09-13 2008-08-27 Smithkline Beecham Corp Hypoglycemic agents methods to manage long-lasting
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
EP1972349A1 (en) * 2007-03-21 2008-09-24 Biocompatibles UK Limited GLP-1 fusion peptides conjugated to polymer(s), their production and use
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
EP1975176A1 (en) * 2007-03-27 2008-10-01 Biocompatibles UK Limited Novel glp-1 fusion peptides, their production and use
MX2009011123A (en) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof.
US8236760B2 (en) * 2007-04-27 2012-08-07 Cedars-Sinsai Medical Center Use of GLP-1 receptor agonists for the treatment of short bowel syndrome
RU2010114044A (en) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) Application of protein band 3 (824-829) and / or the inhibition factor of melanotropine release as a therapeutic against treatment of pseudomonas aeruginosa infection
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
NZ588603A (en) * 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
US20110020345A1 (en) 2008-03-31 2011-01-27 Christopher Herring Drug fusions and conjugates
DK2300031T3 (en) 2008-05-05 2017-10-30 Oramed Ltd Methods and compositions for oral administration of exenatide
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
EP2303247A4 (en) * 2008-07-21 2012-08-01 Syneron Medical Ltd Transdermal system for extended delivery of incretins and incretin mimetic peptides
RU2494755C2 (en) * 2008-08-18 2013-10-10 Интера Био Лтд. Methods and compositions for oral protein administration
BRPI0918904A2 (en) 2008-09-04 2015-12-01 Amylin Pharmaceuticals Inc sustained release formulations using non-aqueous carriers
EP2163243A1 (en) * 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
BR122013025625A2 (en) 2008-10-17 2018-10-30 Sanofi Aventis Deutschland combination of an insulin and a glp-1 agonist, medicine, kit, use and device
DE102008051834A1 (en) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
DE102008053048A1 (en) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
LT2373681T (en) 2008-12-10 2017-04-10 Glaxosmithkline Llc Pharmaceutical compositions of albiglutide
MX2011010151A (en) 2009-03-27 2011-12-14 Glaxo Group Ltd Drug fusions and conjugates.
CN101870728A (en) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 Novel Exendin variant and conjugate thereof
US20120231022A1 (en) 2009-05-28 2012-09-13 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist compounds for sleep enhancement
KR101321461B1 (en) * 2009-08-10 2013-10-29 아크레이 가부시키가이샤 Molecular probe for imaging of pancreatic islet and precursor thereof, and use of the molecular probe or the precursor
DE102009038210A1 (en) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
LT2462246T (en) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CA2774552A1 (en) 2009-09-30 2011-04-07 Glaxo Group Limited Drug fusions and conjugates with extended half life
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
PE20121316A1 (en) 2009-11-13 2012-10-05 Sanofi Aventis Deutschland pharmaceutical composition comprising an agonist of GLP-1 and methionine
KR101836070B1 (en) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
DE102010011919A1 (en) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Liquid composition, useful for treating e.g. type II diabetes mellitus, and/or obesity, comprises a glucagon-like peptide-1 agonist and/or its salt e.g. exendin-4, optionally an adjuvant and methionine
EP2555791B1 (en) 2010-04-09 2017-11-01 Sinai Health System Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CA2797133C (en) 2010-04-27 2019-08-06 Zealand Pharma A/S Peptide conjugates of glp-1 receptor agonists and gastrin and their use
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
LT2611458T (en) 2010-08-30 2016-12-27 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
JP6121330B2 (en) 2010-09-28 2017-04-26 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc Modified polypeptides with increased duration of action
EP2654767A4 (en) 2010-12-22 2014-05-21 Amylin Pharmaceuticals Inc Glp-1 receptor agonists for islet cell transplantation
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP2014521594A (en) 2011-05-25 2014-08-28 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc Long duration dual hormone conjugate
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
JP6006309B2 (en) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc Engineered polypeptides with increased duration of action and reduced immunogenicity
SI2750699T1 (en) 2011-08-29 2015-11-30 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2763691A1 (en) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
WO2013050379A1 (en) 2011-10-04 2013-04-11 Sanofi-Aventis Deutschland Gmbh Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
WO2013064669A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
CN108904810A (en) 2012-01-03 2018-11-30 奥拉姆德有限公司 The method and composition for treating diabetes
EP2814504A4 (en) 2012-02-01 2015-10-14 Oramed Ltd Protease inhibitor-containing compositions, compositions comprising same, and methods for producing and using same
WO2013171570A1 (en) 2012-05-16 2013-11-21 Glaxo Group Limited Polypeptide loaded poca nanoparticles for oral administration
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
AR091422A1 (en) 2012-06-14 2015-02-04 Sanofi Sa Exendin peptide analogs 4
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
AR092925A1 (en) 2012-10-09 2015-05-06 Sanofi Sa Exendin-4 derivatives as dual GLP1 agonists / glucagon
CA2895156A1 (en) 2012-12-21 2014-06-26 Sanofi Dual glp1/gip or trigonal glp1/gip/glucagon agonists
TW201927333A (en) 2013-02-04 2019-07-16 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP2992008B1 (en) 2013-05-02 2019-04-10 GlaxoSmithKline Intellectual Property Development Limited Therapeutic peptides
WO2015055801A1 (en) 2013-10-17 2015-04-23 Zealand Pharma A/S Acylated glucagon analogues
JP2017503474A (en) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ Glucagon-GLP-1-GIP triple agonist compound
TW201605888A (en) 2013-11-06 2016-02-16 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
MX2016008979A (en) 2014-01-09 2016-10-04 Sanofi Sa Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives.
CA2932873A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP2017502051A (en) 2014-01-09 2017-01-19 サノフイ Stabilized pharmaceutical preparation of insulin analogue and / or insulin derivative which does not contain glycerin
TW201625668A (en) 2014-04-07 2016-07-16 Sanofi Sa As the dual peptide of glp-1 / glucagon receptor agonist of exendin-4 derivative
TW201625670A (en) 2014-04-07 2016-07-16 Sanofi Sa Dual derived from glp-1 exendin-4's / glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 Sanofi Sa Derived from exendin -4 (Exendin-4) the dual peptide GLP-1 / glucagon receptor agonists
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
RU2573933C1 (en) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Peptide for medical treatment of pancreatic diabetes of 2nd type and its complications
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017005457A (en) 2014-10-29 2017-07-04 Zealand Pharma As Gip agonist compounds and methods.
CA2970200A1 (en) 2014-12-12 2016-06-16 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
TW201705974A (en) 2015-03-13 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
AU2016247499A1 (en) 2015-04-16 2017-11-02 Zealand Pharma A/S Acylated glucagon analogue
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
KR20180084782A (en) 2015-10-14 2018-07-25 엑스-써마 인코포레이티드 Compositions and methods for reducing ice crystal formation
WO2017112824A2 (en) 2015-12-23 2017-06-29 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
WO2017178829A1 (en) * 2016-04-15 2017-10-19 Imperial Innovations Limited Peptide analogues
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3515408A1 (en) 2016-09-23 2019-07-31 Delpor, Inc. Stable compositions for incretin mimetic compounds
WO2018104263A1 (en) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of enhancing the potency of incretin-based drugs in subjects in need thereof
WO2018237097A1 (en) 2017-06-20 2018-12-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862301A (en) * 1973-06-18 1975-01-21 Stanley M Chernish Glucagon as a diagnostic aid in gastrointestinal radiology
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5130133A (en) * 1990-09-28 1992-07-14 The Procter & Gamble Company Plant extracts as mucosal-protective agents
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
KR100391399B1 (en) * 1993-09-07 2004-02-11 아밀린 파마슈티칼스, 인크. A pharmaceutical composition for gastrointestinal motility regulation
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0662514A1 (en) 1994-01-07 1995-07-12 Ciba-Geigy Ag Hirustasin, an antistasin type serine proteinase inhibitor from Hiruda
AU7637394A (en) 1994-08-26 1996-03-22 Avram Goldstein Analgesic method with dynorphin analogues truncated at the n-terminus
US5574008A (en) * 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5737735A (en) 1996-05-14 1998-04-07 Resolve 2000, Inc. Method and apparatus for recording and reading date data having coexisting formats
AU723694B2 (en) 1996-06-05 2000-08-31 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
DK2016950T3 (en) 1996-08-08 2011-04-04 Amylin Pharmaceuticals Inc Pharmaceutical composition comprising an exendin-4 peptide
CA2468374C (en) 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
AT304864T (en) 1997-01-07 2005-10-15 Amylin Pharmaceuticals Inc Use of exedines and their antagonists to reduce food consumption
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US5846937A (en) * 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
BR9811866A (en) 1997-08-08 2000-08-15 Amylin Pharmaceuticals Inc Compounds agonists of exendin
US6442619B1 (en) 1997-12-31 2002-08-27 Alcatel Usa Sourcing, L.P. Software architecture for message processing in a distributed architecture computing system
CA2365742C (en) 1998-01-09 2013-04-30 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
DE29802348U1 (en) 1998-02-11 1998-04-23 Siemens Ag The electromagnetic current release for an electrical circuit breaker
JP2003522099A (en) 1998-02-27 2003-07-22 ノボ ノルディスク アクティーゼルスカブ Of glp-1 with delayed action profile glp-1 derivatives and exendin
AT265224T (en) 1998-02-27 2004-05-15 Novo Nordisk As GLP-1 derivatives with helix content exceeding 25 forming partially structured micellar aggregates
WO1999047160A1 (en) 1998-03-13 1999-09-23 Novo Nordisk A/S Stabilized aqueous peptide solutions
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
EP1143989B1 (en) 1999-01-14 2006-12-13 Amylin Pharmaceuticals, Inc. Exendins for glucagon suppression
AU2003240822A1 (en) * 2002-05-30 2003-12-19 Human Genome Sciences, Inc. Antibodies that specifically bind to neurokinin b
US6782700B1 (en) * 2004-02-24 2004-08-31 Sunpower, Inc. Transient temperature control system and method for preventing destructive collisions in free piston machines

Also Published As

Publication number Publication date
ES2319936T5 (en) 2013-06-24
CA2262647C (en) 2007-12-04
PT966297E (en) 2009-03-18
US6858576B1 (en) 2005-02-22
AT417622T (en) 2009-01-15
EP0966297A4 (en) 2001-07-11
EP0966297A1 (en) 1999-12-29
DE69739172D1 (en) 2009-01-29
US20090163423A1 (en) 2009-06-25
DK0966297T3 (en) 2009-03-23
US20040266692A1 (en) 2004-12-30
AU4063697A (en) 1998-02-25
DK2016950T3 (en) 2011-04-04
DE69740096D1 (en) 2011-02-17
US20150080307A1 (en) 2015-03-19
JP2001501593A (en) 2001-02-06
WO1998005351A1 (en) 1998-02-12
EP2016950A1 (en) 2009-01-21
EP2016950B1 (en) 2011-01-05
EP0966297B2 (en) 2013-02-27
EP2016950A8 (en) 2009-07-01
EP0966297B1 (en) 2008-12-17
CA2262647A1 (en) 1998-02-12
ES2319936T3 (en) 2009-05-14
US8026210B2 (en) 2011-09-27
JP2008044964A (en) 2008-02-28
US20130331322A1 (en) 2013-12-12
US7521423B2 (en) 2009-04-21
ES2359031T3 (en) 2011-05-17
DK0966297T4 (en) 2013-03-18
US20120004168A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
DE69738301D1 (en) Wirbelsäulendistraktionsimplantat
DE69838851D1 (en) Wirbelsäulendistraktionsimplantat
DE69835685D1 (en) Mehrtransaktionsmünzgerät
DE69837412D1 (en) Ventilpositioniersystem
DE69839729D1 (en) Signallisierungsnetzdurchgangssystem
DE69840810D1 (en) nferenzbreitbanddiensten
DE69840201D1 (en) Verschleissanordnung
DE69832354D1 (en) Netzwerkverwaltungsrahmwerk
DE69824183T2 (en) N-alkanoylphenylalaninderivate
DE69836650D1 (en) Fuseanordnung
DE69840589D1 (en) erungsvorrichtung
DE69838306D1 (en) Sauerstoffanreichungsapparat
DE19810476B4 (en) laryngomaske
DE69841917D1 (en) igarettenpapierbahnen
DE69728678T2 (en) Hydrocolloid-wound gel
DE69834142D1 (en) Tintenzuführsystemadapter
DE69830858D1 (en) Schweinecircoviren
DE69831425D1 (en) Rauchevakuiersystem
DE69827870D1 (en) Drebohrmeissel with moving formation-engaging elements
DE69828310D1 (en) Gelatinzusammensetzungen
DE69839459D1 (en) Gehrungssägeschwenklagerfestspannvorrichtung
DE69829785D1 (en) Signalisierungssytem
DE69832429D1 (en) Wobbelsignalerfassungschaltung
DE69842234D1 (en) Feuchtigkeitskontroleanordnung
DE69838177D1 (en) Androgensyntheseinhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties